Literature DB >> 9435317

Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants.

X Li1, M Shams, J Zhu, A Khalig, M Wilkes, M Whittle, N Barnes, A Ahmed.   

Abstract

Angiotensin II (ANG II) is a potent vasoconstrictor and growth promoter. Quantitative receptor autoradiography using the nonselective radioligand [125I]ANG II and subtype-selective competing compounds demonstrated the presence of both ANG II receptor (AT)1 and AT2 receptor recognition sites. In addition, a relatively small population of apparently non-AT1/non-AT2 sites was identified that may represent a novel high affinity ANG II recognition site in human placenta. Using placental membrane preparations, the AT2 receptor antagonist PD123177 failed to compete for [3H]ANG II binding at relevant concentrations, whereas the AT1 receptor antagonist losartan competed in a monophasic manner for all the specific binding, suggesting that the non-AT1/non-AT2 recognition site identified using autoradiography may be a cytosolic binding site. AT1 receptor binding was significantly reduced (P < 0. 02) in intraeuterine growth restriction (IUGR) pregnancies. Western blot analysis confirmed this showing a reduction in AT1 receptor protein. In situ hybridization and immunocytochemistry revealed that AT1 receptor mRNA and protein were localized throughout pregnancy in the cytotrophoblast, syncytiotrophoblast, and extravillous trophoblast, as well as in or around the blood vessels of placental villi. The intensity of the hybridization signal for AT1 receptor mRNA over the syncytium was reduced in IUGR. ANG II evoked a rapid and concentration-dependent release of NO in first trimester cytotrophoblast-like cells that was abolished by the inclusion of the competitive NOS inhibitor NG-monomethyl-L-arginine. Neither losartan nor PD123177 alone significantly inhibited ANG II-evoked NO release, and when cells were stimulated with ANG II in the presence of losartan (10 microM) and PD123177 (10 microM) in combination, NO release was significantly inhibited (P < 0.05). These observations also suggest, for the first time, the existence of a cross-talk between AT1 or AT2 receptors in trophoblast and that the reduction in placental AT1 receptors in IUGR may, in part, account for poor placental function in this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435317      PMCID: PMC508584          DOI: 10.1172/JCI119881

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Umbilical artery Doppler velocimetry as a predictor of fetal hypoxia and acidosis at birth.

Authors:  S Tyrrell; A H Obaid; R J Lilford
Journal:  Obstet Gynecol       Date:  1989-09       Impact factor: 7.661

2.  Neurohistochemical evidence supporting an absence of adrenergic and cholinergic innervation in the human placenta and umbilical cord.

Authors:  F D Reilly; P T Russell
Journal:  Anat Rec       Date:  1977-07

Review 3.  Are ACE inhibitors safe in pregnancy?

Authors: 
Journal:  Lancet       Date:  1989-08-26       Impact factor: 79.321

4.  Vasomotor responses of the umbilical circulation in fetal sheep.

Authors:  S L Adamson; R J Morrow; S B Bull; B L Langille
Journal:  Am J Physiol       Date:  1989-05

5.  Fetal angiotensin II levels and vascular (type I) angiotensin receptors in pregnancies complicated by intrauterine growth retardation.

Authors:  J C Kingdom; J McQueen; J M Connell; M J Whittle
Journal:  Br J Obstet Gynaecol       Date:  1993-05

6.  Changes in active and inactive renin throughout pregnancy.

Authors:  W A Hsueh; J A Luetscher; E J Carlson; G Grislis; E Fraze; A McHargue
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

7.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.

Authors:  U C Garg; A Hassid
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

8.  Localization of luteinizing hormone-releasing factor in the human placenta.

Authors:  G S Khodr; T Siler-Khodr
Journal:  Fertil Steril       Date:  1978-05       Impact factor: 7.329

9.  Developmental aspects of the renal response to hypoxemia in the lamb fetus.

Authors:  J E Robillard; R E Weitzman; L Burmeister; F G Smith
Journal:  Circ Res       Date:  1981-01       Impact factor: 17.367

10.  Conversion of angiotensin I to angiotensin II in the human foetoplacental vascular bed.

Authors:  T Hosokawa; R B Howard; M H Maguire
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

View more
  24 in total

1.  Intracellular Angiotensin II and cell growth of vascular smooth muscle cells.

Authors:  C M Filipeanu; R H Henning; D de Zeeuw; A Nelemans
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling.

Authors:  Roxanna A Irani; Yujin Zhang; Cissy Chenyi Zhou; Sean C Blackwell; M John Hicks; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

3.  Maternal protein restriction reduces expression of angiotensin I-converting enzyme 2 in rat placental labyrinth zone in late pregnancy.

Authors:  Haijun Gao; Uma Yallampalli; Chandra Yallampalli
Journal:  Biol Reprod       Date:  2012-02-09       Impact factor: 4.285

4.  Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta.

Authors:  E Brailoiu; C M Filipeanu; A Tica; C P Toma; D de Zeeuw; S A Nelemans
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 5.  Angiotensin II regulation of ovine fetoplacental artery endothelial functions: interactions with nitric oxide.

Authors:  Jing Zheng; Ian M Bird; Dong-Bao Chen; Ronald R Magness
Journal:  J Physiol       Date:  2005-03-24       Impact factor: 5.182

6.  Vasoreactivity of chorionic plate arteries in response to vasoconstrictors produced by preeclamptic placentas.

Authors:  C Benoit; J Zavecz; Y Wang
Journal:  Placenta       Date:  2006-10-27       Impact factor: 3.481

7.  Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.

Authors:  Chen Liu; Wei Wang; Nicholas Parchim; Roxanna A Irani; Sean C Blackwell; Baha Sibai; Jianping Jin; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2013-11-04       Impact factor: 10.190

8.  Angiotensin-(1-7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT(1-7) receptor.

Authors:  Lauren Anton; David C Merrill; Liomar A A Neves; K Bridget Brosnihan
Journal:  Endocrine       Date:  2007-11-15       Impact factor: 3.633

Review 9.  Pathophysiology of placentation abnormalities in pregnancy-induced hypertension.

Authors:  Mitsuko Furuya; Junji Ishida; Ichiro Aoki; Akiyoshi Fukamizu
Journal:  Vasc Health Risk Manag       Date:  2008

10.  The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia.

Authors:  Roxanna A Irani; Yujin Zhang; Sean C Blackwell; Cissy Chenyi Zhou; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  J Exp Med       Date:  2009-11-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.